DoubleBlind’s First Coffee Table Book

Whether you are a seasoned psychonaut, a curious skeptic, or looking for the perfect gift for a forward-thinking friend, this book is designed to be lived with.

After seven years of reporting, community building, and being embedded in the middle of a shifting cultural conversation, DoubleBlind co-founders Shelby Hartman and Madison Margolin have turned their work into a single, focused release.

The DoubleBlind Guide to Psychedelics: A Road Map to Tripping, Microdosing, and Beyond (Artisan; April 14, 2026) lands at a moment where psychedelics have clearly moved out of the fringe. What used to live underground is now part of mainstream conversation—from Silicon Valley productivity experiments to more open discussions around mental health and healing.

This book doesn’t try to capitalize on that moment. It tries to bring structure to it.

More Than a Manual: An Integration of Art and Education

DoubleBlind started as a print magazine, but the audience made it clear they needed more than stories. They needed something practical.

The book is the result of that shift. It’s built for people who are past curiosity and want real answers. Not just what these substances are—but how to approach them responsibly, and why that even matters in the first place.

“We started hearing from moms dealing with postpartum depression, veterans seeking healing in the Amazon, and everyday people who just wanted to feel more connected,” the founders reflect.

What’s Inside

This isn’t surface-level coverage. It treats the subject with the weight it deserves.

Psilocybin, LSD, DMT, MDMA, each is broken down in a way that’s clear and usable. No hype. No vague language.

It also covers what most people skip:

dosage
ingestion methods
who should not be taking these substances at all

There’s a strong emphasis on preparation, set and setting, and what happens after the experience. Integration isn’t positioned as optional. It’s the point.

The book also addresses the bigger picture, ethics, commercialization, and the tension between legitimate therapeutic use and opportunistic hype.